Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
2,726
Views
1
CrossRef citations to date
0
Altmetric
Hematology
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
Maria Elisa Mancusoa Centre for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy
https://orcid.org/0000-0002-7113-4028
Giancarlo Castamanb Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Center for Bleeding Disorders, Florence, ItalyCorrespondence[email protected]
https://orcid.org/0000-0003-4973-1317
Michal Pochopienc Creativ-Ceutical, Krakow, Poland
, Samuel Aballéad Creativ-Ceutical, Rotterdam, The Netherlands
, Aleksandra Drzewieckac Creativ-Ceutical, Krakow, Poland
https://orcid.org/0000-0003-3396-8571
Zalmai Hakimie Swedish Orphan Biovitrum Ltd, Stockholm, Sweden
https://orcid.org/0000-0001-5835-8599
Jameel Nazire Swedish Orphan Biovitrum Ltd, Stockholm, Sweden
& Francis Fatoyef Faculty of Health and Education, Manchester Metropolitan University, Manchester, UK
https://orcid.org/0000-0002-3502-3953
Pages 1068-1075
|
Received 08 Jun 2022, Accepted 18 Aug 2022, Published online: 06 Sep 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.